Anti-EXOSC5 (aa 1-185) polyclonal antibody

Antibody Isotype

IgG

Species Reactivity

Human

Immunogen

Recombinant fragment, corresponding to a region within amino acids 1-185 of Human EXOSC5 (UniProt Q9NQT4).

Conjugate

Application Notes

IHC-P: 1/100 - 1/1000; ICC/IF: 1/100 - 1/1000.

Alternative Names

EXOSC5; exosome component 5; exosome complex component RRP46; exosome component Rrp46; hRrp46p; MGC12901; p12B; RRP41B; RRP46; Rrp46p; exosome complex exonuclease RRP46; ribosomal RNA-processing protein 46; chronic myelogenous leukemia tumor antigen 28; M

Entrez Gene ID

UniProt ID

Antigen Description

Non-catalytic component of the RNA exosome complex which has 3->5 exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding pervasive transcripts, such as anti-sense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3 untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes.

Pathway

Activation of Genes by ATF4; Deadenylation-dependent mRNA decay; Destabilization of mRNA by Butyrate Response Factor 1 (BRF1); Destabilization of mRNA by KSRP; Destabilization of mRNA by Tristetraprolin (TTP); Diabetes pathways; Disease